Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Share-based Compensation (2019 - 2026)

Atea Pharmaceuticals' Share-based Compensation history spans 8 years, with the latest figure at $3.7 million for Q1 2026.

  • Quarterly Share-based Compensation fell 46.35% to $3.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $17.5 million through Mar 2026, down 62.07% year-over-year, with the annual reading at $20.7 million for FY2025, 59.97% down from the prior year.
  • Share-based Compensation came in at $3.7 million for Q1 2026, down from $4.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.3 million in Q4 2024 to a low of $3.7 million in Q1 2026.
  • The 5-year median for Share-based Compensation is $11.9 million (2022), against an average of $10.1 million.
  • Year-over-year, Share-based Compensation surged 60.33% in 2022 and then tumbled 67.93% in 2025.
  • Atea Pharmaceuticals' Share-based Compensation stood at $11.6 million in 2022, then increased by 4.4% to $12.2 million in 2023, then rose by 17.6% to $14.3 million in 2024, then crashed by 67.93% to $4.6 million in 2025, then decreased by 18.67% to $3.7 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Share-based Compensation are $3.7 million (Q1 2026), $4.6 million (Q4 2025), and $4.5 million (Q3 2025).